New PM – Bolette Buchner Vinum
Welcome to our new Project Manager Bolette Buchner Vinum has a Master of Science (MSc) in Biotechnology and has been working at the Laboratory for Molecular Cardiology at the Heart Centre of Rigshospitalet, Copenhagen University Hospital prior to NSGO-CTU. We’re very excited to have her join out team. arrow-icon-size3 Back To Overview
ENGOT-EN6/GOG-3031/NSGO-RUBY STUDY
Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer. “This is a great milestone for our […]
AGO-OVAR 17 BOOST/GINECO
Results from AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 The Novemeber edition of the American Society of Clinical Oncology has published “Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial” ABSTRACT PURPOSE To compare standard versus extended duration of bevacizumab treatment in combination […]
ESGO 2022 – A great success
ESGO 2022 / Berlin Thank you, European Society of Gynaecological Oncology Berlin 2022. Several of NSGO-CTU PI’s attended the conference as speakers and guest. Mansoor Raza Mirza, NSGO-CTU’s Medical Director & Vice-President of ESGO had the honor of presenting the prestigious Helga Salvesen Award 🏆 for a major contribution in translational research to Prof Iain McNeish from the Imperial College […]
New PM – Stine Randeris
Welcome to our new Project Manager Welcome to our new Project Manager at NSGO-CTU. Stine Randeris is a registered nurse and has a Master of Science (MSc) in Global Health and has been working at the clinical trial unit Phase I prior to NSGO-CTU. We’re very excited to have her join out team. arrow-icon-size3 Back […]
NSGO-CTU Office Themeday – Workshop at Mansoor’s
NSGO-CTU Theme day – Sep. 2022 Twice a year, the Project Managers of NSGO-CTU gets together for a day north of Copenhagen, in the home of our Medical Director, Mansoor. Each workshop has a theme, where the PM’s are set specific task related to the advancement of our method of work. This years theme was […]
OReO/ENGOT-ov38 – IGCS22 / New York
OReO/ENGOT-ov38 PRO data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer. International Gynecologic Cancer Society http://ow.ly/cxCh50L0j4b #IGCS2022 #gynsm #cancer #oncology arrow-icon-size3 Back To Overview
Mansoor Raza Mirza in Toronto – MyGoals
Toronto Our Medical Director, Dr. Mirza was in Toronto yesterday to give a Keynote Lecture on the topic “Maintenance PARP inhibitors treatment decisions, controversies, and challenges” MyGOALS Oct. 2022 arrow-icon-size3 Back To Overview
ENGOT meeting in Berlin, Sep. 2022
ENGOT meeting 15th annaversary Berlin, Sep. 2022 NSGO-CTU’s Medical Director, Dr. Mansoor Raza Mirza and Deputy Medical Director, Kristine Madsen attended the annual ENGOT meeting in Berlin last week. Dr. Mirza is currently Chair of ENGOT. Project Manager Christina Sidsel Dalsgaard and Mia Sejer Donner (NSGO-CTU ENGOT rep.) also attended the meeting with the ENGOT operationals. Previous Next arrow-icon-size3 Back To […]
Paola-1/ENGOT – OV25 trial
Results from Paola-1 ENGOT/OV25 The October edition of The European Journal of Cancer (EJC) has published “Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial” The results were presented by Dr. Isabelle Ray-Coquard at ESMO – European Society for Medical Oncology in Paris last month. #EuropeanJournalofCancer #EJC #PAOLA #ENGOT #clinicaltrial #ovariancancer #NSGO arrow-icon-size3 Back To […]
